Article
Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies
15 Apr 2011
Abstract excerpt
The strand-exchange engineered domain (SEED) platform was designed to generate asymmetric and bispecific antibody-like molecules, a capability that expands therapeutic applications of natural antibodies. This new protein engineered platform is based on exchanging structurally related sequences of immunoglobulin within the conserved CH3 domains. Alternating sequences from human IgA and IgG in the SEED CH3 domains...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
